About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 63414 record(s)
Req # A-2022-000343
All available communications to and from Minister of Health Jean-Yves Duclos mentioning the word “Fisman”. All briefing notes, reports and presentations given by Minister Jean-Yves Duclos mentioning the word “Fisman”. Date range of March 1, 2021 to June 14th, 2022.Organization: Health Canada
June 2022
Req # A-2016-001731
Adverse Drug Reaction (ADR) for zopliclone. Report number: E2B_00459587.Organization: Health Canada
June 2022
Req # A-2017-001373
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 17-102637-367.Organization: Health Canada
June 2022
Req # A-2018-001398
Adverse Drug Reactions (ADRs). Report numbers: 703638, 703644, 704449, 707867, E2B_01525133, E2B_01578736, E2B_01605838, E2B_01612357, E2B_01620703, E2B_01654772, E2B_01670148, E2B_01670197, E2B_01705710, E2B_01706646, E2B_01712961, E2B_01727469, E2B_01727469, E2B_01731911, E2B_01736971, E2B_01738885, E2B_01745892, E2B_01748366, E2B_01751456, E2B_01754774 , E2B_01787560, 2B_01788179, E2B_01813266, E2B_01818804, E2B_01818811, E2B_01832718, E2B_01833864,701361, 701670, 703200, E2B_01463953, E2B_01496945, E2B_01564266, E2B_01571621, E2B_01683502, E2B_01688688 , E2B_01691939, E2B_01745232, E2B_01839494, E2B_02023140, E2B_01753291, E2B_01835937, E2B_02023140, 704310, E2B_01337229, E2B_01390001, E2B_01437165, E2B_01504512, E2B_01531289, E2B_01593582, E2B_01610092, E2B_01626626, E2B_01626951, E2B_01647717, E2B_01743835, E2B_01754339, E2B_01754739, E2B_01755978, E2B_01780372, E2B_01801470, E2B_01811492, E2B_01812577, E2B_01821773.Organization: Health Canada
June 2022
Req # A-2019-001134
Adverse Drug Reactions (ADRs). Report numbers: E2B_02432928, E2B_02450489, E2B_02470140, E2B_02477341, E2B_02486392, E2B_02467423, 000725317, E2B_02456900, E2B_02424831.Organization: Health Canada
June 2022
Req # A-2019-001210
Adverse Drug Reactions (ADRs). Report numbers: E2B_02057852, E2B_02063318, E2B_02128406, E2B_02130380, E2B_02123168, E2B_02127169, E2B_02095893, E2B_02273662, E2B_02050568, E2B_02036824, E2B_02069544, E2B_02129763, E2B_02124251, E2B_02276517, E2B_02368928, E2B_02234025, E2B_02284874, E2B_02277058, E2B_02276686, E2B_02277057, E2B_02266421, E2B_02055844, E2B_02055005, 000721458, E2B_02052618, E2B_02272700, E2B_02052601.Organization: Health Canada
June 2022
Req # A-2020-001053
Adverse Drug Reactions (ADRs). Report numbers: 000559596, 000615961, 000718467, 000723899, 000724879, 000726161, 000726163, 000726164, 000726165, 000726167, 000726170, 000726172, 000726174, 000726175, 000726182, 000726195, 000726206, 000726253, 000726257, 000726261.Organization: Health Canada
June 2022
Req # A-2020-001063
Adverse Drug Reactions (ADRs). Report numbers: 000726583, 000726584, 000726593, 000726595, 000726597, 000726598, 000726612, 000726643, 000726647, 000726648, 000726651, 000726671, 000726674, 000726792, 000726801, 000726828, 000726832, 000726837, 000726848.Organization: Health Canada
June 2022
Req # A-2020-001073
Adverse Drug Reactions (ADRs). Report numbers: 000917175, E2B_03222251, E2B_03251118, E2B_03258746.Organization: Health Canada
June 2022
Req # A-2020-001354
Adverse Drug Reactions (ADRs). Report numbers: E2B_02297406, E2B_02310649, E2B_02329607, E2B_02359198, E2B_02359200, E2B_02290951, E2B_02304756, E2B_02310622, E2B_02310639, E2B_02315336, E2B_02356160, E2B_02356162, E2B_02356163, E2B_02362328.Organization: Health Canada
June 2022